Ligand Pharma (LGND) PT Raised to $326 at Oppenheimer

August 3, 2026 5:51 AM

Oppenheimer analyst Leland Gershell raised the price target on Ligand Pharma (NASDAQ: LGND) to $326.00 (from $285.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found